Losartan & Irbesartan NDMA Lawsuits 2026: the $15.26M Settlement Is Closed — but the Cancer Claims Are Still Alive
The short answer: the $15.26 million class settlement covering recalled valsartan, losartan, and irbesartan closed its claim window on June 2, 2026 and received final approval on June 30, 2026. But that deal paid only economic losses. Personal-injury and medical-monitoring claims were never included — and that track is still moving in federal court.
- The combined economic-loss fund: $15.26 million — Hetero (valsartan) $11,365,489.80; Aurobindo (irbesartan) $2,000,000; Vivimed (losartan) $1,899,000.
- Claim deadline: June 2, 2026; final approval: June 30, 2026, before Judge Renee M. Bumb in Camden, New Jersey.
- The case: In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation, MDL No. 19-MD-2875, District of New Jersey.
- The contamination: nitrosamines NDMA, NDEA, and NMBA — classified as probable human carcinogens — found in recalled generic sartans beginning in 2018.
Why a Closed Settlement Doesn't End Your Case
A closed claim window does not mean the litigation is finished. The three 2026 settlements were deliberately narrow: they reimbursed economic losses — what people paid for medications that, the lawsuits allege, should never have been sold. The court papers are explicit that personal-injury and medical-monitoring claims are not included. Those are being litigated separately, inside the same multidistrict litigation. If you took recalled losartan or irbesartan and later developed a serious illness, the June 2 deadline does not necessarily describe your situation — but statutes of limitation vary by state, so time still matters.
What NDMA, NDEA, and NMBA Actually Are
Nitrosamines are chemical compounds that can form as unintended byproducts of certain manufacturing processes. NDMA, NDEA, and NMBA are three members of that family. Regulators classify them as probable human carcinogens — a label used when animal studies show clear cancer risk and the limited human evidence points the same way. They were never ingredients in the pills; they were trace impurities introduced by how the active pharmaceutical ingredient was synthesized — enough, the FDA decided, to trigger recalls.
How Losartan and Irbesartan Got Pulled Into the Crisis
The scandal began with valsartan in 2018 but did not stay there. As the FDA and manufacturers widened testing, the same nitrosamine impurities turned up in other drugs of the sartan family — the blood-pressure medicines also called ARBs (angiotensin II receptor blockers), drugs that relax blood vessels by blocking a hormone that tightens them. Nationwide recalls swept generic losartan and irbesartan products manufactured between 2012 and 2019, from multiple generic manufacturers. For losartan the impurity at issue included NMBA; for irbesartan, NDEA and NDMA. Three of America's most-prescribed blood-pressure drugs ended up in one federal lawsuit.
MDL 2875, Explained in Plain English
An MDL — multidistrict litigation — is a federal procedure that gathers similar lawsuits from across the country before one judge for pretrial proceedings. MDL No. 19-MD-2875, before Judge Renee M. Bumb in New Jersey, became the single forum for the sartan contamination cases: economic-loss, personal-injury, and medical-monitoring claims alike. The same consolidation device carries many other drug cases — see, for example, the Onglyza heart-failure MDL.
The $15.26 Million, Broken Down
The combined figure was not one fund but three, each tied to a defendant and run through a single claim system with one shared deadline — the structure we detailed in our breakdown of the valsartan settlement. Hetero — $11,365,489.80 (valsartan): purchasers of valsartan containing Hetero's Process III active ingredient, sold May 1, 2018 to July 31, 2018. Aurobindo — $2,000,000 (irbesartan): purchasers of irbesartan made with Aurobindo's active ingredient, from January 1, 2016 onward. Vivimed — $1,899,000 (losartan): purchasers of Vivimed losartan formulations under eight specific impacted National Drug Codes. All three companies deny wrongdoing.
The Personal-Injury Track: What Is Still Open in 2026
This is what the settlement headlines leave out. The economic-loss deals say nothing about whether the impurities caused any individual's cancer — that question belongs to the personal-injury cases, which allege long-term exposure to NDMA, NDEA, or NMBA in contaminated sartans contributed to cancers and other serious conditions. Those claims must prove, person by person, both exposure and causation — a far higher bar than showing you bought a recalled pill, which is precisely why they were excluded from the $15.26 million deal. Attorneys continue to evaluate these cases within the MDL.
What to Do If You Took Recalled Losartan or Irbesartan
First, ask your pharmacy for dispensing records showing the manufacturer and NDC of every losartan or irbesartan prescription — pharmacies keep these for years, and they are the single most useful document you can have. Second, check your lots against the FDA's public list of recalled ARBs. Third, gather medical records if you were diagnosed with cancer or a related condition after long-term use. Fourth, speak with a product-liability attorney promptly: most firms in this field work on contingency — the lawyer is paid only if the case recovers money — so an early review costs nothing. If you missed the June 2, 2026 window, say so upfront; a good attorney will tell you in minutes whether the still-open injury track fits your facts. Drug-settlement tracks often run on separate schedules — as the PPI settlement process shows — so an early review is the only way to know which deadlines actually apply to you.
General information only — not legal or medical advice. For guidance about your situation, consult a qualified attorney in your state.
For more plain-English breakdowns of drug and consumer litigation, see our channel: Problem Solved.
Who Benefits From This — and Who Does Not
A closed claim window does not mean the litigation is finished: the 15.26 million dollar deal paid only economic losses, while the personal-injury track was never included. Your situation depends on which track you are on.
Who benefits:
- People who took recalled losartan or irbesartan and later developed a serious illness: Personal-injury and medical-monitoring claims were never part of the closed settlement and are still being litigated in MDL 2875 — but state statutes of limitation still apply, so get an evaluation promptly.
- People checking whether their product was actually recalled: Recalls covered specific manufacturers lots sold roughly 2012 to 2019, including Vivimed losartan under eight specific National Drug Codes — check pharmacy records against the FDA list of recalled ARBs rather than guessing from the brand name.
- People who need the two tracks kept apart: The closed fund reimbursed what people paid for the drugs; the continuing cases seek compensation for bodily harm and medical monitoring — different plaintiffs, different proof, different recovery.
Who benefits little or not at all:
- Anyone seeking money from the closed 15.26 million dollar fund now: Its claim window closed on June 2, 2026, with final approval on June 30, 2026 — a new economic-loss claim cannot be filed into it.
- Anyone assuming the companies admitted causation: Hetero, Aurobindo and Vivimed all deny wrongdoing and dispute that the nitrosamine levels found were harmful or carcinogenic.
- Purchasers whose only loss was the price paid and who missed the deadline: That economic track is closed; only a separate personal-injury or medical-monitoring claim, if one exists, could still be pursued.
Related reading: valsartan NDMA settlement breakdown.
Frequently Asked Questions
I missed the June 2, 2026 deadline. Is there really nothing left for me?
Not necessarily. The closed fund covered only economic losses — what you paid for the drugs. Personal-injury and medical-monitoring claims were separate and were never part of that settlement, so missing the claim window does not automatically end an injury case. State statutes of limitation still apply, so get an evaluation promptly.
What is the difference between the settlement that closed and the lawsuits that continue?
The closed $15.26 million deal reimbursed consumers and payors for money spent on allegedly contaminated medication. The continuing cases seek compensation for bodily harm — conditions plaintiffs attribute to nitrosamine exposure — plus medical monitoring. Different plaintiffs, different proof, different recovery.
Which losartan and irbesartan products were recalled?
The recalls covered specific manufacturers' lots sold over roughly 2012–2019, including Vivimed losartan under eight specific NDCs and irbesartan made with Aurobindo's active ingredient. The authoritative reference is the FDA's public list of recalled ARBs — check it against your pharmacy records rather than guessing from the brand name on the bottle.
Do the drug companies admit the contamination caused cancer?
No. Hetero, Aurobindo, and Vivimed all deny wrongdoing and dispute that the nitrosamine levels found were harmful or carcinogenic. Whether exposure caused any individual's illness remains a question the personal-injury cases must prove in court.
Who benefits most from the still-open track?
People who took recalled losartan or irbesartan and later developed a serious illness — personal-injury and medical-monitoring claims were never included in the closed 15.26 million dollar economic-loss settlement and are still being litigated in MDL 2875, though state statutes of limitation still apply, so an evaluation should not wait.
Who cannot get money from the closed settlement now?
Anyone whose only claim is the money paid for the drugs and who missed the June 2, 2026 claim window — that fund, finally approved June 30, 2026, covered economic losses only, and the companies deny wrongdoing, so a new economic claim cannot be filed into it.